22 June 2017 
EMA/CHMP/398319/2017  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Faslodex 
fulvestrant 
On 22 June 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Faslodex. The 
marketing authorisation holder for this medicinal product is AstraZeneca UK Ltd. 
The CHMP adopted a new indication as follows2: 
“Faslodex is indicated for the treatment of postmenopausal women with estrogen receptor positive, 
locally advanced or metastatic breast cancer in postmenopausal women: 
•  not previously treated with endocrine therapy, or 
• 
for with disease relapse on or after adjuvant antiestrogen therapy, or disease progression 
on therapy with an antiestrogen therapy.” 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
